The family of autoimmune and inflammatory disorders where CXCL13 appears to be involved in disease pathogenesis and constitutes an attractive therapeutic target includes, among others, Multiple Sclerosis (MS) [23-26], Rheumatoid Arthritis (RA) [27-30]; Hashimoto’s thyroiditis [31], chronic gastritis/MALT lymphoma [32,33], graft rejection syndrome [34], Sjogren’s Syndrome [35]; Systemic Lupus Erythematosis [36], and Myastenia Gravis [37]. This evidence concerns the gene CXCL13 and multiple sclerosis.